2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Phosphodiesterase (PDE)

Phosphodiesterase (PDE)

Phosphodiesterase (PDE)

Related Products

PDF 4.17 MB

Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules.

Phosphodiesterase (PDE) Isoform Specific Products:

Phosphodiesterase (PDE) Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-186214
    PDE4-IN-36
    		Inhibitor
    PDE4-IN-36 is a phosphodiesterase 4 (PDE4) inhibitor with significant inhibitory activity at 10 μM. PDE4-IN-36 can be used in the research of psoriasis and atopic dermatitis.
    PDE4-IN-36
  • HY-151174
    PDE4-IN-12
    		Inhibitor
    PDE4-IN-12 is a potent pan-PDE4 inhibitor, with IC50s of 3.5 and 15 nM for PDE4 and PDE7, respectively (SI=2.71 and 4.27, respectively). PDE4-IN-12 shows well tolerated, can be used in study of inflammatory bowel diseases (IBDs).
    PDE4-IN-12
  • HY-136520S
    Xanthoanthrafil-d3
    Xanthoanthrafil-d3 is the deuterium labeled Xanthoanthrafil (HY-136520B). Xanthoanthrafil is a potent phosphodiesterase-5 (PDE5) inhibitor, with an IC50 of 3.95 ng/mL. Xanthoanthrafil can be used for the research of erectile dysfunction.
    Xanthoanthrafil-d<sub>3</sub>
  • HY-105057
    MDL 19205
    		Agonist
    MDL 19205 is a cardiotonic agent with inotropic effect. MDL 19205 can be used for the research of cardiovascular disease, such as heart failure.
    MDL 19205
  • HY-123008
    Reproterol hydrochloride
    		Inhibitor
    Reproterol hydrochloride is a dual-acting beta2-adrenoceptor agonist and phosphodiesterase inhibitor. Reproterol hydrochloride is more potent than albuterol and feterol in stimulating cAMP production in human monocytes, demonstrating its potential in enhancing airway function. Furthermore, Reproterol significantly inhibited the production of LTB4, indicating its anti-inflammatory properties. Reproterol hydrochloride may have inhibitory effects in respiratory diseases such as asthma and COPD.
    Reproterol hydrochloride
  • HY-181762
    Multitarget AD-IN-6
    		Inhibitor
    Multitarget AD-IN-6 (Compound 39) is a multi-target inhibitor, with an IC50 of 15.54 μM against PDE4B, 15.15 μM against PDE7A, 8.39 μM against PDE3A, and a Kd of 37.7 μM against CHIT1. Multitarget AD-IN-6 acts as a TRPA1 antagonist, reduces the level of the NLRP3 inflammasome multiprotein complex to inhibit its activation, while inhibiting PDE4B, PDE7A and CHIT1, and decreasing the phosphorylation of NF-κB. Multitarget AD-IN-6 improves the pathology of elastase-induced emphysema in mice. Multitarget AD-IN-6 is applicable for the research of chronic obstructive pulmonary disease.
    Multitarget AD-IN-6
  • HY-W982613
    SCA-40
    		Inhibitor
    SCA-40 is a vasodilator for bronchial smooth muscle. SCA-40 produces biphasic relaxation on bronchi with spontaneous tension, and the relaxation effect is not inhibited by various potassium channel blockers. SCA-40 can be used for research on bronchial conditions.
    SCA-40
  • HY-165395
    AY 25674
    		Inhibitor
    AY 25674 is an orally active antiallergic agent and a PDE inhibitor. AY 25674 inhibits the release of allergic histamine from mast cells. AY 25674 suppresses passive anaphylaxis induced by reaginic (IgE) antibodies. AY 25674 does not inhibit the increased vascular permeability caused by non-reaginic antibodies, serotonin or histamine. AY 25674 reaches its peak activity shortly after administration; rapid tolerance occurs at high doses. AY 25674 can be used in research related to passive anaphylaxis.
    AY 25674
  • HY-119316A
    CM-545
    		Inhibitor
    CM-545, the cis-isomer of CM-414 (HY-119316), is a dual inhibitor of PDE5, HDAC1, HDAC2, HDAC3, and HDAC6 with pIC50 values of 7.47, 6.65, 6.14, 6.55, and 6.84, repectively.
    CM-545
  • HY-14841
    Gisadenafil
    		Inhibitor
    Gisadenafil (UK-369003) is a specific, orally active phosphodiesterase 5 (PDE5) inhibitor with an IC50 of 3.6 nM and prevents degradation of cyclic guanosine monophosphate (cGMP).
    Gisadenafil
  • HY-132821B
    (R)-Irsenontrine
    		Inhibitor 99.00%
    (R)-Irsenontrine ((R)-E2027), the R-enantiomer of Irsenontrine (HY-132821), is a potent phosphodiesterase 9 (PDE9) inhibitor with an IC50 value of 0.041 μM. (R)-Irsenontrine can be used for the research of neurological diseases.
    (R)-Irsenontrine
  • HY-153766
    PDE5-IN-9
    		Inhibitor 98.0%
    PDE5-IN-9 (Compound 59) is a PDE5 inhibitor (IC50: 11.2 μM). PDE5-IN-9 shows interaction with Gln 817, Tyr 612, and Ala 767 amino acid residues. PDE5-IN-9 can be used for research of cardiovascular disease.
    PDE5-IN-9
  • HY-153733
    PDE5-IN-8
    		Inhibitor
    PDE5-IN-8 (compund 2) is a PDEs inhibitor.
    PDE5-IN-8
  • HY-169300
    KR-40795
    		Inhibitor
    KR-40795 is a potent inhibitor of ATX (autotaxin), with the IC50 of 0.13 μM. KR-40795 plays an important role for liver diseases.
    KR-40795
  • HY-172870
    PDE4B-IN-4
    		Inhibitor
    PDE4B-IN-4 (Compound 11E) is a PDE4B (IC50: 2.82 nM) and TNF-α (IC50: 7.20 nM) inhibitor. PDE4B-IN-4 inhibits neutrophilia in a mouse lipopolysaccharide (LPS)-induced sepsis model and exhibits anti-inflammatory activity.
    PDE4B-IN-4
  • HY-B0442CR
    Vardenafil dihydrochloride (Standard)
    		Inhibitor
    Vardenafil (dihydrochloride) (Standard) is the analytical standard of Vardenafil (dihydrochloride). This product is intended for research and analytical applications. Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM respectively, while IC50s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes-.
    Vardenafil dihydrochloride (Standard)
  • HY-165439
    Indolidan
    		Inhibitor
    Indolidan (LY195115) is an orally active cardiotonic agent and a selective cyclic nucleotide phosphodiesterase inhibitor. Indolidan has a Ki of 80 nM for sarcoplasmic reticulum phosphodiesterase (SR-PDE). Indolidan exhibits positive inotropic and vasodilator effects. Indolidan can be used in the research of diseases such as congestive heart failure.
    Indolidan
  • HY-153334
    Enpp-1-IN-15
    		Inhibitor
    Enpp-1-IN-15 (Compound 88a) is an Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (Enpp-1) Inhibitor, with a Ki value of 0.00586 nM.
    Enpp-1-IN-15
  • HY-176520
    PDE4-IN-29
    		Inhibitor
    PDE4-IN-29 (Compound 55) is an orally active and selective PDE4 inhibitor (including subtypes such as PDE4A1, PDE4B2, PDE4D3) with IC50s of <5 nM against PDE4D3. PDE4-IN-29 inhibits the degradation of cyclic adenosine monophosphate (cAMP), increases intracellular cAMP levels, suppressing the release of inflammatory factors such as TNF-α. PDE4-IN-29 is promising for research of inflammatory diseases including psoriasis, atopic dermatitis, and chronic obstructive pulmonary disease.
    PDE4-IN-29
  • HY-15455S2
    Roflumilast-d3
    		Inhibitor
    Roflumilast-d3 is deuterium labeled Roflumilast. Roflumilast is a selective PDE4 inhibitor with IC50s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells.
    Roflumilast-d<sub>3</sub>
Cat. No. Product Name / Synonyms Application Reactivity
Phosphodiesterase (PDE) Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.